Clinical Trial Update: Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)

View source ↗

Summary

Real-world clinical study evaluating outcomes for metastatic castration-resistant prostate cancer patients treated with the olaparib and abiraterone combination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-resistant Prostate Cancer | Status: RECRUITING